Paul Duic

2.2k citations
5 papers · 1.3k indexed · 1 hit paper · h-index 3

Impact in

Papers in

Paul Duic

5 papers receiving 1.2k citations

Hit Papers

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma 2008 · 1.2k citations
1.2k20082026201420204008001.2k

Peers

Paul Duic
Comparison fields: 5 of 65
  • Genetics 1.0k
  • Cancer Research 335
  • Neurology 205
  • Pulmonary and Respiratory Medicine 393
  • Structural Biology 14
Replace Nancy Garren with:
Nancy Garren United States
Leighann Bailey United States
Andrey Golanov Russia
Dana Cernea Romania
Soufiane El Hallani Canada
Magdalena C. Ƶlatescu Canada
Lynn S. Ashby United States
Brian Thiessen Canada
Daniel Schrimpf Germany
V. Blatt Italy
Paul Duic relative to Nancy Garren United States Nancy Garren's profile →
Citations per field
00.5×1.5×
Nancy Garren · 1×
Citations per year

Countries citing papers authored by Paul Duic

Since Specialization
Citations

This map shows the geographic impact of Paul Duic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Duic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Duic more than expected).

Fields of papers citing papers by Paul Duic

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Duic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Duic. The network helps show where Paul Duic may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Paul Duic, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul Duic Line = papers co-authored together Paul Duic links everyone, so they are left out of the graph.

All Works

5 of 5 papers shown
#Work
1 20241
2 20233
3 20211
4 200940
5
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Hit paper breakdown →
20081211

About Paul Duic

Paul Duic is a scholar working on Genetics, Pharmaceutical Science, Neurology, Oncology and Cancer Research, having authored 5 papers that have together received 1.3k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (3 papers), Brain Metastases and Treatment (2 papers), Pancreatic and Hepatic Oncology Research (1 paper), Neuroblastoma Research and Treatments (1 paper), Bone health and treatments (1 paper), Radiopharmaceutical Chemistry and Applications (1 paper), Microtubule and mitosis dynamics (1 paper) and Cancer, Hypoxia, and Metabolism (1 paper). The work is most often cited by research in Genetics (1.0k citations), Cancer Research (335 citations), Neurology (205 citations), Pulmonary and Respiratory Medicine (393 citations) and Structural Biology (14 citations). Paul Duic has collaborated with scholars based in United States and Israel. Frequent co-authors include Teri Kreisl, Howard A. Fine, Kraig Moore, Lyndon Kim, Paul S. Albert, Nancy Garren, John A. Butman, Kevin Camphausen, John Park and Megan Mackey. Their work appears in journals such as Clinical Cancer Research, Frontiers in Oncology, Journal of Clinical Oncology, Annals of Oncology and Neuro-Oncology Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026